GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
EconoTimes4d
GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
pharmaphorum2d
ERS: GSK reveals data behind new asthma hope depemokimab
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
FiercePharma4d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
pharmaphorum4d
GSK rides out vaccine sales weakness with cancer, HIV gains
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
GSK lifts long-term sales outlook on strong Specialty Medicines growth
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...
National Institute for Health and Care Excellence2d
Awaiting development: Guidance and quality standards
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769] Technology appraisal guidance Depemokimab for treating chronic rhinosinusitis with nasal polyps ...
National Institute for Health and Care Excellence2d
Awaiting development: Guidance and quality standards
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable [ID6249] Technology appraisal guidance Depemokimab for treating ...